15 ropinirol, kan det derfor være nødvendigt at justere dosis af ropinirol, når lægemidler der vides at hæmme CYP1A2, f. eks. ciprofloxacin, enoxacin eller fluvoxamin introduceres eller seponeres.
Hence, in patients already receiving ropinirole, the dose of ropinirole may need to be adjusted when medicinal products known to inhibit CYP1A2, e. g. ciprofloxacin, enoxacin or fluvoxamine, are introduced or withdrawn.